Clinical diagnostics company Beckman Coulter disclosed on Thursday the receipt of the US Food and Drug Administration's (FDA) 510(k) clearance to market the DxH 520 hematology analyzer in the laboratories, clinics and physician offices in the US.

The company added that the DxH 520 features unique technology that improves sample flagging by 40%, ensuring better first-pass yield and accurate differentials with as little as 17 microliters of blood. Its accurate, rapid and reliable results with a small drop of blood makes its ideal for neonate, pediatric and critical-care patients.

According to the company, the DxH 520 includes five part differential testing in a compact and cost-effective package, small sample volume requirement well suited to patients with difficult blood draws, only three screen touches to access any menu, cost-effective, easy waste disposal as well as closed tube analyzer for enhanced safety.

In conjunction, the company's DxH 520's closed tube aspiration capability reduces manual steps and ensures safety for laboratorians by eliminating sample exposure and risk of contact with blood-borne pathogens. The analyzer features a robust patient data and quality control (QC) management system that allows for easy retrieval from a vast storage database of up to 30,000 patient samples--or over 16 months of clinical data in heavy-use scenarios.

Concurrently, the DxH 520's friendly reagents reagents are water-based and cyanide-, azide- and formaldehyde-free. This approach eliminates the disposal costs associated with competitive systems that employ multiple reagents and/or harsh solvents, concluded the company.